P ositron emission tomography-computed tomography (PET-CT), utilizing 18-fl uoro-2-deoxyglucose (FDG), is a widely accepted modality for initial and subsequent treatment planning of many malignancies (1). Accurate staging of disease is imperative for treatment planning. Studies have shown that PET-CT is more sensitive than conventional staging alone (2) and that hybrid PET-CT is more accurate than either modality used in isolation (3). With the increased utilization of PET-CT, there has been increased awareness of the possibility of detecting an unsuspected synchronous malignancy. Studies have shown that PET-CT can detect an unexpected synchronous malignancy in up to 4.8% of patients with a known malignancy (4) . Risk factors such as smoking, alcohol consumption, or genetics may predispose a patient toward developing a synchronous malignancy, with the most common locations being the lung, breast, and colon (5) . Detection of an unsuspected malignancy can have signifi cant impact on a patient's treatment plan and prognosis, and misinterpretation of these fi ndings as metastatic lesions can lead to incorrect upstaging of the primary tumor.
While PET-CT has a higher sensitivity than conventional staging alone, it is also nonspecifi c, and areas of increased F-18 FDG uptake may represent benign or malignant processes. Th e most common sites of nonmalignant increased uptake of radiotracer are within the bowel and thyroid gland (4) . Knowledge of the normal physiologic distribution of F-18 FDG as well as common variants is essential for accurate interpretation of PET-CT. In addition, knowledge of the expected pattern of spread for commonly imaged diseases can increase sensitivity in detecting lesions that are outside the expected pattern of spread. Utilization of the localization CT images can increase specifi city and decrease the falsepositive rate.
NORMAL FDG DISTRIBUTION
FDG is a glucose analog and marker for metabolism. As such, FDG can localize within both benign and malignant tissues. Normal biodistribution includes high levels of uptake within the central nervous system and genitourinary system. Low-grade uptake is expected within the liver and spleen. Variable uptake is seen within the myocardium and the gastrointestinal system. Breast and thyroid uptake is also variable but tends to be symmetrical and of low intensity (6) (Figure 1) .
In addition to recognizing these areas of expected physiologic distribution, it is useful to have knowledge of commonly seen areas of abnormal but nonpathologic uptake. A common cause for abnormally increased FDG uptake within the neck and chest is brown adipose tissue activation. High FDG uptake can be seen in areas that correlate with adipose tissue on the localization CT. Brown adipose tissue activation is most commonly seen in pediatric patients and females (7) (Figure 2) .
Skeletal muscle can have low-grade uptake; however, if the patient has undergone strenuous activity within a few days preceding the injection, signifi cant skeletal muscle uptake can also be seen (6) . Utilizing a muscle group during the uptake phase can also result in increased physiologic FDG activity. In addition, phonation prior to imaging can result in symmetric activity in the larynx, involving the vocal cords and posterior cricoarytenoid muscles; jaw clenching or chewing prior to imaging can show activation of muscles of mastication (8); and insulin administration or a nonfasting state can cause diff use skeletal muscle uptake since insulin drives glucose (and FDG) into skeletal muscles (9) (Figure 3 ). Knowledge of these and additional variations is particularly helpful when evaluating a patient with a known head and neck carcinoma or lymphoma. c Bone marrow uptake is typically low to moderate with a standardized uptake value <3; however, in patients who have undergone chemotherapy, bone marrow uptake can be intense, particularly in patients undergoing treatment with granulocyte colony-stimulating factor (10) (Figure 4 ).
EXPECTED PATTERNS OF METASTASES
In interpreting PET-CT results, a general understanding of the physiology of a disease and its expected pattern of metastases is needed. Diseases that spread hematogenously will have a more diff use pattern of spread, with a heavier burden of metastases in the liver and lungs due to fi rst pass drainage. Diseases that spread via lymphatics will fi rst drain to regional lymph nodes. Mesenchymal malignancies often spread by direct extension.
Breast cancer
Breast cancer spreads both through lymphatic drainage pathways and hematogenous dissemination. In the majority of breast cancers, lymphatic spread often precedes hematogenous spread; however, hematogenous spread can occur early in the disease process. Lymphatic spread follows lymphatic drainage pathways, most commonly involving the ipsilateral axilla and internal mammary chain. Hematogenous metastases involve the liver and bone, with less common involvement of the lungs and brain (11) (Figure 5 ).
Despite the unpredictable metastatic pattern, breast cancer often has a sequence of metastases. An isolated pulmonary lesion in the absence of axillary, hepatic, or bone lesions is unlikely. Often the localization CT images can help diff erentiate between metastatic and nonmetastatic lesions. In general, pulmonary metastases often have a rounded appearance with a b relatively smooth margins, whereas a primary pulmonary malignancy will appear more spiculated or ground glass in appearance (Figures 6 and 7) .
Non-small cell lung cancer Distant metastases are present at diagnosis in 10% to 35% of patients with non-small cell lung cancer. Non-small cell lung cancer spreads via locoregional lymph nodes, with ipsilateral hilar and mediastinal nodes involved early in the disease. If the primary tumor is subpleural in location, direct invasion of the chest wall or mediastinum can be seen. Th e most common locations for extrathoracic metastases include supraclavicular lymph nodes, adrenal glands, liver, bone, and brain (12) (Figures 8, 9 , and 10). 
Head and neck cancer
Squamous cell carcinoma of the head and neck most commonly spreads via lymphatics to regional lymph nodes. Due to venous drainage through the superior vena cava, distant spread is most commonly seen within the lungs, with liver metastases occurring less frequently.
Head and neck cancers are more frequently associated with unsuspected synchronous malignancies, predominantly within the upper digestive and respiratory tract. Th is is hypothesized to be related to the carcinogenic eff ects of alcohol and tobacco on the upper aerodigestive tract. A second primary malignancy is the leading cause of treatment failure and death in patients with early stage squamous cell carcinoma of the head and neck, making detection and proper characterization vital to the proper treatment of a patient (14) (Figures 11, 12, and 13 ).
CONCLUSION PET-CT has been shown to detect unexpected synchronous malignancies in up to 4.8% of patients. When present, these lesions can signifi cantly alter patient management and prognosis. Knowledge of normal variants and expected patterns of spread can increase sensitivity for the detection of a synchronous malignancy, and correlation with cross-sectional imaging, including the localization CT, can be helpful to increase the specifi city of unexpected fi ndings on PET-CT. There is intense symmetric diffuse uptake within the thyroid, suggesting thyroiditis. Subtle mildly increased uptake is seen within the right renal fossa. This would be an uncommon site for metastatic disease; however, it is also not one of the most common locations for associated malignancy. (b and c) The area of uptake correlates with a deformed enlarged superior pole of the right kidney on the localization CT. This was a primary renal cell carcinoma, which was isointense to renal parenchyma.
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